Objective: To systematically evaluate the literature on the therapeutic use of Schwann cells (SC) in the repair of peripheral nerve injuries.

Methods: The Cochrane Library and PubMed databases were searched using terms ["peripheral nerve injury" AND "Schwann cell" AND "regeneration") OR ("peripheral nerve injuries"). Studies published from 2008 to 2022 were eligible for inclusion in the present study. Only studies presenting data from in-vivo investigations utilizing SCs in the repair of peripheral nerve injuries qualified for review. Studies attempting repair of a gap of ≥10 mm were included. Lastly, studies needed to have some measure of quantifiable regenerative outcome data such as histomorphometry, immunohistochemical, electrophysiology, or other functional outcomes.

Results: A search of the PubMed and Cochrane databases revealed 328 studies. After screening using the abstracts and methods, 17 studies were found to meet our inclusion criteria. Good SC adherence and survival in conduit tubes across various studies was observed. Improvement in morphological and functional outcomes with the use of SCs in long gap peripheral nerve injuries was observed in nearly all studies.

Conclusion: Based on contemporary literature, SCs have demonstrated clear potential in the repair of peripheral nerve injury in animal studies. It has yet to be determined which nerve conduit or graft will prove superior for delivery and retention of SCs for nerve regeneration. Recent developments in isolation and culturing techniques will enable further translational utilization of SCs in future clinical trials.

KEYWORDS
Schwann cells (SCs), peripheral nerve, nerve regeneration, Schwann cell transplantation, nerve repair
Introduction

It has been estimated that 2–3% of all patients admitted to Level 1 Trauma centers present with a peripheral nerve injury, and injury to peripheral nerves has been observed in 1.64% of patients who experience trauma to the upper or lower extremities (Noble et al., 1998; Taylor et al., 2008). A recent study revealed an overall peripheral nerve injury incidence rate of 36.9 per 1,000,000 person years in sport, exercise, and recreational injuries presenting to the emergency room from 2009 to 2018 (Li et al., 2021). These injuries can be devastating to patients, resulting in potential losses of both sensory and motor function in the affected distribution, and are associated with significant costs to health system infrastructure (Karsy et al., 2019; Bergmeister et al., 2020).

Short-segmental gap peripheral nerve injuries can be readily repaired by end-to-end suturing, autologous nerve transplantation, processed nerve allografting, and conduit implementation. Long-gap peripheral nerve injuries, however, have posed significant challenges to surgeons and require novel approaches to effectively restore nerve patency and enhance post-operative return of function. The “critical” gap length for long-gap injuries has been established as 3 cm in humans and 10–15 mm in rats, the model most commonly utilized in peripheral nerve repair studies (Lundborg et al., 1982; Francel et al., 1997; Kaplan et al., 2015). Longer nerve defects (>5 cm) have been shown to independently correlate with significantly worse outcomes for patients (Roganovic et al., 2005). Autologous sural nerve transplantation, long-considered the gold standard for repair of these injuries, poses multiple limitations. Sural nerve harvesting can increase patient morbidity by necessitating a separate incision and leading to potential injury due to sensory loss. Limitations in nerve supply for autologous transplantation in repair of nerves with large cross-sectional areas, such as in sciatic and femoral nerve transections, may lead to suboptimal outcomes (Barks et al., 2021). Nerve allografts and conduits have been investigated as alternatives to harvesting nerves for autologous grafting (Angius et al., 2012). Allografted nerves containing living cells require treatment with immunosuppressant agents to mitigate rejection, and though processed nerve grafts and acellular conduits alone have been implemented successfully in short-gap nerve repair, their use for long-gap repair remains controversial with mixed results (Midha et al., 1993; Den Dunnen et al., 1996; Isaacs and Browne, 2014; Muheremu and Ao, 2015; Leckenby et al., 2020; Safa et al., 2020).

In an effort to overcome some of these difficulties, researchers have explored the use of Schwann cells (SCs) to repair peripheral nerve injuries (Mosahebi et al., 2002; Hood et al., 2009; Han et al., 2019). In the peripheral nervous system, SCs myelinate axons and are the primary source of structure and support. These cells secrete neurotrophic factors into their micro-environments that promote axonal regeneration and nerve fiber extension after peripheral nerve injury. The regenerative effect conferred by SCs is not limited to the PNS and has been observed in the central nervous system as well (Bachelin et al., 2005; Kocsis and Waxman, 2007). As SCs have exhibited robust capabilities in facilitating axonal repair and regeneration, they carry great potential as a candidate for transplant therapy in long-segmental peripheral nerve injuries.

Harvesting, purifying, and expanding populations of SCs for autologous transplant has proved to be exceedingly difficult until recent years. The purpose of this systematic review is to detail the current role of SC implementation in peripheral nerve repair, and to outline current limitations as well as future clinical applications and directions for this technology.

Methodology

Literature search strategy

We searched PubMed and Cochrane databases to find articles published on this review topic. The following terms were utilized: ["peripheral nerve injury" AND "Schwann cell" AND "regeneration"] OR ["peripheral nerve injuries"]). Our search was limited to studies published in English and was updated until March 27, 2022. Upon removal of duplicates, two researchers screened each study independently, reviewing their abstracts and methodology to ascertain whether each would be pertinent to this study. Finally, included studies were reviewed in their entirety and discussed herein. See PRISMA checklist.

Inclusion criteria

Studies published in English from 2008 to 2022 were eligible for inclusion in the present study. Additionally, to be included, it was necessary for studies to have available abstracts for initial screening purposes. Studies were required to present data from in-vivo studies utilizing Schwann cells in the repair of peripheral nerve injuries with a gap of ≥10 mm. Lastly, studies needed to have some measure of quantifiable regenerative outcome data such as histomorphometry, immunohistochemistry, electrophysiology, or other functional outcomes reported.

Exclusion criteria

Studies published in languages other than English as well as those published prior to 2008 were excluded from the present study. Studies which did not include abstracts were excluded. Review articles, opinion pieces, and studies which presented...
purely *in-vitro* data were excluded. Studies investigating lesions to the central nervous system such as spinal cord injuries were excluded. Articles in which stem-cells were utilized and differentiated to Schwann cell phenotypes and those that did not report quantifiable outcomes were excluded.

**Results**

A preliminary query of the PubMed and Cochrane databases revealed 328 studies from 2008 to 2022 (Figure 1). After an initial screening using the abstracts and methods, 17 studies were found to meet our inclusion criteria.

These 17 studies in which Schwann cells were used in transplantation are reviewed in Table 1. Studies on SC transplantation spanned from 2008 to 2021. Five studies utilized acellular nerve allografts, four used varying iterations of chitosan-based conduits, two studies used PCL based conduits, two used collagen-based conduits, one study used a silicone conduit, one used a cellulose conduit, one study investigated a conduit made from electro-spun Perfluorotributylamine (PFTBA), and the remaining study utilized two nanocomposite-based conduits made of silk fibroin. Thirteen studies reported the concentration of SCs loaded into the nerve conduits. Studies ranged from 4 to 52 weeks with a mean study period of ∼14 weeks.
| References          | Animal model            | Nerve gap | Controls used                       | Experimental groups                                                                 | Cell type   | Number of transplanted cells | Study period | Conduit used                  |
|---------------------|-------------------------|-----------|-------------------------------------|-------------------------------------------------------------------------------------|-------------|-----------------------------|--------------|--------------------------------|
| Aszmann et al., 2008| Sprague-Dawley and Lewis Rats | 30 mm     | homologous matrix only without Schwann cell, autograft | Study groups were (1) SD acellular autograft covered with SCs from proximal neuroma (2) Lewis rats with acellular homograft covered with SCs from proximal neuroma | Autologous SCs | 12 weeks                    | Acellular auto- or homograft |
| Chang, 2009         | Sprague-Dawley Rats     | 15 mm     | Isograft                            | Conduit filled with (1) Genipin non-crosslink (2) low crosslink (3) medium crosslink (4) high crosslink | Autologous SCs | 8 weeks                     | Polycaprolactone (PCL), genipin-crosslinked gelatin |
| Sun et al., 2009    | Wistar Rats             | 10 mm     | Autograft                           | Conduit filled with (1) SCs (2) Acellular                                           | Autologous SCs | 12 weeks                    | Acellular nerve allograft  |
| McGrath et al., 2010| Fischer Rats            | 10 mm     | Autograft                           | Conduit filled with (1) BDTM PuraMatrix™ peptide (BD) hydrogel (2) Conduit filled with BDTM PuraMatrix™ peptide (BD) hydrogel plus SCs (3) Conduit filled with alginate/fibronectin hydrogel (4) Conduit filled with alginate/fibronectin hydrogel plus SCs | Autologous SCs | 16 weeks                    | Cellulose conduit  |
| Berrocal et al., 2013| Fischer and Lewis Rats for reversed autograft | 15 mm     | Autograft                           | Conduit filled with (1) GFP negative SCs (2) GFP positive SCs (3) serum only          | Autologous SCs | 16 weeks                    | NeuraGen™       |
| Jesuraj et al., 2014| Lewis Rats              | 14 mm     | Isograft, cold preserved acellular nerve graft with no SCs | Conduit filled with (1) SCs derived from sciatic nerve (2) SCs derived from femoral motor (3) SCs derived from femoral sensory | Autologous SCs | 7 weeks                     | Cold preserved acellular nerve graft |
| HOBEN et al., 2015  | Lewis Rats              | 20 mm     | Isograft                            | (1) isograft (2) ANA (3) ANA-SCs (4) ANA-VEGF                                       | Autologous SCs | 10 weeks                    | Acellular nerve allograft |
| Wang et al., 2017   | Nerve donors were ICR mice and graft recipients were C57BL/6 mice | 10 mm     | Acellular nerve allograft alone     | Study groups (1) SF conduit plus SCs (2) KLF7-SCs                                    | Allogenic SCs | 4 weeks                     | Acellular nerve allograft |
| Das et al., 2017    | Sprague-Dawley Rats     | 10 mm     | Sciatic nerve left untreated        | Study Groups (1) Silk fibroin conduit (2) Silk fibroin conduit plus SCs (3) PASF conduit (4) PASF conduit plus SCs | Rat Schwann cell line (SCTM41) | 52 weeks                    | Silk Fibroin (SF) or Polyaniline-silk (PASF) nanocomposite-based |

(Continued)
| References          | Animal model       | Nerve gap | Controls used              | Experimental groups                                                                 | Cell type               | Number of transplanted cells | Study period | Conduit used                                |
|---------------------|--------------------|-----------|----------------------------|--------------------------------------------------------------------------------------|-------------------------|----------------------------|--------------|---------------------------------------------|
| Liu et al., 2017    | Sprague-Dawley Rats | 15 mm     | Autograft                  | Study Groups (1) magnetic scaffold (2) magnetic scaffold under MF exposure (3) SC-loaded magnetic scaffold (4) SC-loaded magnetic scaffold under MF exposure | Autologous SCs          | -                          | 12 weeks     | Magnetic nanocomposite scaffold, chitosan-glycerophosphate polymer |
| Ma et al., 2018     | Sprague-Dawley Rats | 15 mm     | Autograft                  | Conduit filled with (1) SC and fibrin hydrogel (2) PFTBA alone without SCs (3) PFTBA plus SCs | Autologous SCs          | $2 \times 10^8$ GFP-expressing SCs in 10 ml fibrinogen solution | 12 weeks     | Chitosan-collagen                           |
| Gonzalez-Perez et al., 2018 | Wistar Hannover rats (Janvier) | 15 mm | Acellular fibronectin enriched conduit or laminin enriched conduit | Conduit filled with (1) collagen-fibronectin 20% plus MSCs (2) collagen-fibronectin 20% plus SCs (3) collagen-laminin 20% plusMSCs (4) collagen-laminin 20% plus SCs | Allogenic SCs            | $7.5 \times 10^5$ cells. The pellet was resuspended in 1 ml | 16 weeks     | Chitosan                                    |
| Huang et al., 2019  | Sprague-Dawley Rats | 10 mm     | Conduit filled with Matrigel and SCs | Conduit filled with (1) c-jun transfected SCs continuously treated with Dox for 12 wk (2) c-jun transfected SCs treated with no Dox for the entire experimental period (Dox$\sim12$) (3) c-jun transfected SCs treated with Dox for 3 wk followed by removal of Dox for 9 wk (Dox$\sim9$) | Autologous SCs          | SCs and matrigel (2 $\times$ $10^7$ cells/ml) | 12 weeks     | Poly (ε-caprolactone) (PCL)                  |
| Ma et al., 2020     | Sprague-Dawley Rats | 17 mm     | Autograft                  | Conduit filled with (1) SCs without PFTBA injected into (fibers + gel) (2) SCs without PFTBA injected into (PFTBA fibers + gel) (3)SC-gel mixtures with PFTBA injected into (PFTBA-gel) (4) SC-gel with PFTBA injected into (PFTBA fibers + PFTBA-gel) | Autologous SCs          | $1 \times 10^6$ SCs          | 12 weeks     | Perfluorotributylamine                      |
| Burks et al., 2021  | Fischer Rats       | 13 mm     | Autograft, NeuraGen™ filled with Serum only | Conduit filled with green fluorescent protein (GFP)-labeled SCs | Autologous SCs          | $1 \times 10^5$ cells/µl | 16 weeks     | NeuraGen™ 3D                                |
| Muangsanit et al., 2021 | Wistar Rats        | 10 mm     |                          | Conduit filled with (1) SCs (2) HUVEC (3) SC-HUVEC combination | Rat Schwann cell line SCL4.1/F7 | 100 µl of cell suspension (culture medium containing 0.5–4.0 $\times$ $10^6$ cells/mL) | 4 weeks      | Silicone tube collagen gel                  |
| Yao et al., 2021    | Sprague-Dawley Rats | 10 mm     | Conduit filled with PBS    | Conduit filled with (1) Lentivirus control SCs (2) Lv-lox680254 SCs | Autologous SCs          | -                          | 12 weeks     | Chitosan                                    |
SC adherence and survival in conduit tubes

SCs were observed to have good adherence and displayed a homogenous distribution upon implantation in conduit tubes (Sun et al., 2009; McGrath et al., 2010; Berrocal et al., 2013; Das et al., 2017; Huang et al., 2019; Burks et al., 2021; Muangsanit et al., 2021). SCs also demonstrated good survival. In Berrocal et al. (2013), GFP fluorescence of autologous SCs was detected up to 16 weeks after implantation. Optimization in SC survival was observed with use of a perfluorotributylamine (PFTBA) fibrin hydrogel, an oxygen carrier, within a chitosan conduit in Ma et al. (2018). They observed a significantly greater survival of GFP labeled SCs within the PFTBA conduit up to 28 days after implantation as compared to the conduits with SCs but without the hydrogel. In Ma et al. (2020), the authors demonstrated further enhancement of SC survival in a conduit designed with a core-shell structure containing encapsulated PFTBA. The new scaffold coupled with the PFTBA hydrogel allowed for greater oxygen carrying capacity and increased SC survival during the initial hypoxic phase of nerve regeneration. Similarly, Liu et al. (2017) demonstrated improvement in SC viability and distribution in a magnetically responsive scaffold upon exposure to a magnetic field.

Improvement in myelinated axons

Nerve regeneration was assessed through various morphologic measurements, including number of myelinated axons, axonal area/diameter, and myelin thickness. Although significant interstudy differences exist regarding the graft employed for repair, gap length, and time point for measurements, there is near complete consensus among animal studies that supplementing nerve grafts with Schwann cells in the repair of critical nerve gap defects enhances nerve regeneration.

There were 15 studies (Aszmann et al., 2008; Sun et al., 2009; McGrath et al., 2010; Berrocal et al., 2013; Jesuraj et al., 2014; Hoben et al., 2015; Liu et al., 2017; Wang et al., 2017; Gonzalez-Perez et al., 2018; Ma et al., 2018, 2020; Huang et al., 2019; Burks et al., 2021; Yao et al., 2021) that evaluated the number of myelinated axons within the graft through light microscopy and/or through immunostaining. Among those, 14 studies demonstrated significant improvement in myelinated axon counts in the graft with SCs as compared to the graft alone (Aszmann et al., 2008; Sun et al., 2009; McGrath et al., 2010; Berrocal et al., 2013; Jesuraj et al., 2014; Hoben et al., 2015; Liu et al., 2017; Wang et al., 2017; Gonzalez-Perez et al., 2018; Ma et al., 2018, 2020; Huang et al., 2019; Burks et al., 2021; Yao et al., 2021). The presence of regenerated myelinated axons in the middle of a 10-mm gap were observed as early as 10–14 days after surgery (Huang et al., 2019; Yao et al., 2021) and in the distal end of a 10-mm gap as early as 3–4 weeks (McGrath et al., 2010; Liu et al., 2017; Huang et al., 2019). Yao et al. (2021) observed that in a 10-mm gap repaired with a chitosan scaffold and injected with either native SCs or SCs transfected with a long coding RNA (loc680254) shown to increase SC proliferation, regenerated axons grew up to 5–6 mm past the proximal stump as compared to 2 mm for the empty scaffold at 10 days after surgery. In McGrath et al. (2010), regenerating axons were observed to reach as far 15.88 mm from the proximal stump in a 10-mm gap repaired with a membrane conduit filled with a BF™ PuraMatrix™ peptide (BD) hydrogel and SCs. Axons in the BD hydrogel group without SCs reached a mean distance of 8.56 mm. Hoben et al. (2015) demonstrated no significant difference in the number of total nerve fibers regenerated between isograft and acellular nerve graft loaded with SCs at 10 weeks.

In nearly all studies that employed a reversed autograft group as a positive control (McGrath et al., 2010; Berrocal et al., 2013; Liu et al., 2017; Ma et al., 2018, 2020; Burks et al., 2021; Muangsanit et al., 2021) the repair group with implanted SCs demonstrated statistically similar number of myelinated axons as the reversed autograft group that regenerated to the distal segment of the graft used to repair gaps ranging from 10 to 17 mm between 4 and 16 weeks after surgery. Of note, although Aszmann et al. (2008) observed that the number of myelinated axons at the distal segment of a much longer gap, about 30 mm, bridged with a homologous nerve graft that was seeded with harvested SCs were significantly fewer, smaller in diameter and had thinner myelination as compared to the autograft group at 12 weeks after surgery, they performed significantly better than the empty grafts, which did not have any axons reach the distal end.

Retrograde labeling also demonstrated a high level of neuronal regeneration with significant improvement in the number of spinal motoneurons and DRG sensory neurons with the addition of SCs that was not statistically different from the reversed autograft repair (McGrath et al., 2010; Liu et al., 2017; Wang et al., 2017; Huang et al., 2019; Ma et al., 2020). Interestingly, Huang et al. (2019) demonstrated that upregulation of neurotrophic factor expression in tetracycline-responsive transcriptional activator (Tet-On/c-Jun)-transduced SCs improved neuronal regeneration of both sensory and motor neurons with doxycycline treatment in a time-restricted manner as compared to repair with wild type SCs.

Regenerated axon morphology was measured either through axonal area (Berrocal et al., 2013; Gonzalez-Perez et al., 2018) or diameter (Aszmann et al., 2008; Chang, 2009; Liu et al., 2017; Wang et al., 2017; Ma et al., 2018, 2020). As with axon count, the repair of long gaps with grafts supplemented with SCs demonstrated larger areas (Berrocal et al., 2013; Gonzalez-Perez et al., 2018) and diameters...
Das et al. (2017); McGrath et al. (2010) was the only study that observed no motor recovery and frequently observed a significant increase in the tibialis anterior muscle fiber areas at 12 weeks. Studies performed motor end plate analysis on the tibialis anterior muscle and observed a significant increase in the number of motor end plates among the groups with SCs and were not statistically different from the reversed autograft group (Liu et al., 2017; Ma et al., 2018, 2020). Azizmann et al. (2008) was the only study that observed no motor and poor sensory recovery in all groups.

**Effects on microvasculature**

There were two studies that looked at the effects on microvasculature with microvessel density (MVD) measurements within the repair site (Liu et al., 2017; Ma et al., 2018), Ma et al. (2018) observed a significant increase in MVD with SC supplementation. Specifically, they explored the use of PFTBA fibrin hydrogel, as an oxygen carrier, within collagen chitosan conduits to increase oxygenation of SCs. Although the group with the PFTBA hydrogel and SCs had the greatest MVD, SC supplementation without the PFTBA hydrogel had greater MVD than the groups repaired with the standard fibrin hydrogel alone and the PFTBA hydrogel alone. Similarly, in a study by Liu et al. (2017) looking at the effects of a magnetic nanocomposite scaffold (MG) with an applied magnetic field (MF) to supplement long gap nerve repair, groups with implanted SCs demonstrated significantly greater MVD than both non-SC groups, MG alone and MG with MF. However, the group with SCs and an applied magnetic field demonstrated the best MVD. These studies suggest that SCs are able to independently stimulate vascularization, which may be further enhanced by an additional stimulus, such as improvement in oxygenation. Though Hoben et al. did not measure objective outcomes relating to graft vascularity, they demonstrated that acellular nerve grafts supplemented with VEGF alone were inferior to acellular nerve grafts loaded with SCs (Hoben et al., 2015).

**Functional recovery**

Motor functional recovery was assessed through neurophysiological studies, specifically through conduction studies and compound muscle action potential (CMAP) waveform analysis. Nearly all studies demonstrated enhanced CMAP amplitudes among the respective group with implanted SCs (Sun et al., 2009; Das et al., 2017; Wang et al., 2017; Ma et al., 2018, 2020; Burks et al., 2021), all measured at varying times that ranged from 4 weeks to 12 months. Conduction velocities and latencies, mostly measured at the gastrocnemius and occasionally at the tibialis anterior, were also observed to significantly improve in the SC groups (Sun et al., 2009; Das et al., 2017; Wang et al., 2017; Ma et al., 2018, 2020; Burks et al., 2021). In Burks et al. (2021), onset latencies at the level of the gastrocnemius were observed to be statistically similar between the SC group, the reversed autograft group and the contralateral uninjured control and all were significantly shorter than the conduit alone.

Sensory recovery was assessed by measuring thermal withdrawal latency (Azizmann et al., 2008; Liu et al., 2017; Wang et al., 2017; Gonzalez-Perez et al., 2018; Ma et al., 2018, 2020). Although good sensory recovery among all groups was observed in most studies, there were a few studies where SC groups demonstrated significantly quicker responses to thermal stimuli than all other groups and were statistically similar to the reversed autograft group (Liu et al., 2017; Ma et al., 2018, 2020). Azizmann et al. (2008) was the only study that observed no motor and poor sensory recovery in all groups.

The extent of muscle recovery following denervation was assessed either through measuring the gastrocnemius muscle fiber areas or with muscle weights. The largest gastrocnemius muscle fiber areas at 12 weeks were observed among the SC groups and were not statistically different from the reversed autograft groups (Liu et al., 2017; Ma et al., 2018, 2020). Similarly, the SC groups were also observed to have significantly greater muscle weight recovery as compared to the non-SC groups in some studies (Wang et al., 2017; Burks et al., 2021). However, in McGrath et al. (2010), best muscle weight recovery at 16 weeks was observed among the autograft group, followed by the BD hydrogel conduits and then the standard alginate/fibronectin hydrogel conduits. The addition of SCs were not observed to impart any statistical improvement in muscle recovery in any of the hydrogel conduits. Interestingly, upregulation of neurotrophic factor expression in Tet-On/c-Jun-transduced SCs in Huang et al. (2019), also significantly increased muscle fiber areas and muscle weight in time-restricted manner as compared to wild type SCs. Lastly, Wang et al. (2017) performed motor end plate analysis on the tibialis anterior muscle and observed a significant increase in the number of motor end plates among the groups with SCs as compared to the non-SC group. These results suggest that SCs may aid in reducing muscle atrophy, possibly by enhancing neuronal regeneration of motor neurons and increasing motor end plates.

Finally, significant improvement in hindlimb functional recovery with SC implantation as measured by sciatic functional index (SFI) scores from walking track analysis was observed in a few studies (Liu et al., 2017; Ma et al., 2018, 2020; Burks et al., 2021; Yao et al., 2021). In contrast, Das et al. (2017) did not observe improvement in SFI scores with SC implantation, and instead observed that improvement was more dependent on the conduit composition.
Discussion

Past

Physicians and scientists have long grappled with the challenges of peripheral nerve repair and nerve regeneration. In the fifth century BC, Hippocrates stated in his works, *On the Articulations and Aphorisms*, that care should be taken to avoid overstretching nerves, and that cut nerves would neither unite nor be restored (Belen et al., 2009). Further advancements were made by Galen in the second and early third centuries, as he identified that nerves were responsible for varying functions, and that injury or loss resulted in, what was thought to be, permanent insensitivity and paralysis. In the seventh century, Paul of Aegina, a Byzantine Greek physician, first described an attempt at peripheral nerve repair (Paulus, 1528). Experiments done on the glossopharyngeal and hypoglossal nerve of frogs led to the characterization of neuronal degeneration after injury, described by Augustus Waller in the 1850s (Waller, 1851). In the late 1800s, Gluck attempted to use a piece of hollow bone as a nerve conduit to repair peripheral nerve injury. This unsuccessful effort was followed by several experiments by Vanlair, who was able to achieve nerve regeneration using a similar conduit made of bone (Battiston et al., 2005).

The implementation of aseptic surgical technique at the turn of the century made peripheral nerve repair increasingly possible, and the dawn of human genomics has provided researchers with abundant frontiers to explore in this area. In the past several decades, we have experienced the birth and evolution of synthetic conduits for use in peripheral nerve repair, starting as hollow tubes made from silicone and transforming into meticulously engineered structures made from biomaterials such as collagen, chitosan, and cellulose. These conduits have been further augmented in recent years to include neurotrophic factors to aid in SC recruitment, and ultimately loaded with SCs themselves in an effort to improve nerve regeneration.

Present

Peripheral nerve repair continues to pose unique challenges to surgeons and patients alike. Long considered the gold standard, harvesting the sural nerve for transplantation requires an additional surgery, increasing the chance for iatrogenic complications, post-operative infection, as well as infliction of added sensory deficits along the nerve’s distribution. This procedure has the potential to result in neuroma formation leading to neuropathic pain, as well as additional time repositioning and operating. In a study of 478 sural nerve harvest procedures, 92.9% of patients experienced sensory deficits, nearly 19.7% experienced chronic pain post-operatively, and 5.7% were complicated by wound infection at the harvest site (Kawamura et al., 2010; Ducic et al., 2020). Additionally, the ability to repair peripheral nerve injuries is limited by the supply of sural nerve, which may be insufficient, especially in the case of large diameter or long gap injuries. Furthermore, as there are anatomic variations from patient to patient, the cross-sectional area of the sural nerve may not be sufficient to adequately bridge a sciatic nerve transection, for example. A recent meta-analysis on 3,974 limbs revealed a pooled mean length of the sural nerve to be 14.78 (±5.76) cm with a mean diameter of 0.28 (±0.03) cm (Ramakrishnan et al., 2015). The sciatic nerve is known to have a diameter of ~2 cm, roughly 6.5 times greater than the average sural nerve. Therefore, peripheral nerve surgeons have resulted in commonly prioritizing coaptation of the medial fibers of the sciatic nerve in hopes of maximizing motor function over restoration of sensation in the peroneal division (Gousheh et al., 2008; Burks et al., 2014). Taken together, the autograft has long been the gold-standard for peripheral nerve gap repair, but this technique has many drawbacks and alternative strategies are warranted.

Autologous SC loaded nerve conduits have continuously adapted over time, with modifications to their composition as well as their intra-luminal structures. Recent advancements in technology have allowed for the development of nerve conduits made from silicon, collagen, polycaprolactone (PCL), chitosan, and various other synthetic polymers to bridge peripheral nerve gaps and provide a scaffold to guide nerve regeneration. From 1995 to 2012, 11 neural regeneration guide devices were approved for use by the FDA (Kehoe et al., 2012). Hollow synthetic tubes were the first generation of conduits employed, but use of these tubes were largely limited to small-gap injuries and improvements in design were needed to target longer gaps (De Ruiter et al., 2009).

Recently, second-generation and tissue-engineered axon guidance channels were developed from biomaterials with the goal of more closely mimicking natural perineurium anatomy, providing increased porosity and optimized architecture within the larger bore tube to aid in the longitudinal growth of regenerating axons (Gaudin et al., 2016; Stewart et al., 2020). Coupled with the structural advancements made, strides have also been made in optimizing the cocktail and concentration of neurotrophic factors, cell types, as well as exosomes and nanoparticles that conduits may be supplemented with. Though commercialization of nerve conduits has allowed for increased availability to surgeons, autografts and allografts continue to outperform conduits in their current forms (Mauch et al., 2019; Herman and Ilyas, 2020). However, the supplementation of Schwann cells within the conduits offers promise in improving outcomes.

Taken together, the results of our systematic review provide strong evidence that conduits loaded with autologous SCs are significantly superior to conduits alone in improving axonal regeneration and functional outcomes after long-gap peripheral nerve injury. Additionally, conduits loaded with SCs performed...
statistically similar to reverse autografts in the seven studies in which positive controls were implemented.

Berrocal et al. (2013) demonstrated at our own institution that conduits or processed nerve allografts loaded with autologous SCs enhanced regeneration of myelinated axons as compared to an acellular tube. With these promising results in mind, the first in-human autologous SC use was performed at our institution in 2015 (Levi et al., 2016). A sural nerve biopsy and tissue sample from traumatized sciatic nerve stumps was taken in order to expand a population of autologous SCs. Sural nerve grafts were combined with an FDA-approved collagen matrix, which was seeded with the autologous human SCs, bridging a 7.5 cm gap. The patient demonstrated improvement in plantar flexion, from 0/5 to 4/5, at 18 months after surgery. The safety and feasibility of this procedure was corroborated by a second case at our institution in which a gunshot wound that resulted in a 5 cm partial disruption of the tibial division of the sciatic nerve was repaired in a similar manner. The patient regained all motor function associated with the tibial nerve and partial sensation (Gersey et al., 2017). More recently, the first phase 1 clinical trial for transplantation of autologous SCs in chronic spinal cord injury demonstrated that transplants were well-tolerated with no significant adverse events occurring (Gant et al., 2022).

Though these clinical outcomes are extremely promising, widespread implementation of this technology would not be feasible without a standardized and reproducible protocol for SC isolation and expansion in culture. Our group has published extensively on the investigation and refinement of protocols for successful SC harvesting and propagation in animal and, more recently, human subjects. Once it had been established that adult rat SCs could be cultured whilst maintaining their ability to myelinate neurons, the process of optimizing the right combination of neural growth factors in cell culture began (Morrissey et al., 1991). Shortly thereafter, the initial work on harvesting and expanding human SCs using the proper mitogens took place (Levi and Bunge, 1994; Casella et al., 1996). These human SCs were successfully transplanted into the peripheral nerves of immune deficient mice, however these grafts did not function as well in bridging an 8 mm nerve defect as grafts containing autologous murine SCs (Levi et al., 1994). This experimentation established NGF, BDNF, CNF, and rHRG, best in combination with CAMP, as crucial neurotrophic factors and potent mitogens in the promotion of neural regeneration (Levi et al., 1995). Additionally, the number of cell-culture passages in order to obtain high SC purity was reduced (Levi, 1996). Then, in 1997, a study at our institution was undertaken to repair a 15 mm nerve gap in primates using autologous SCs in a nerve conduit. These results demonstrated that, although the sural autograft group was superior, all groups regained some degree of functionality with the sural autograft and SC infused conduit groups performing better in electrophysiological outcomes (Levi et al., 1997).

More recently, we published our optimized protocol for human autologous SC isolation, purification, and expansion, in which the average yield per patient was 87.2 ± 89.2 million cells at P2 and 150.9 ± 129.9 million cells at P3 with over 90% purity and viability (Khan et al., 2022). Utilizing this protocol, investigators can reliably harvest human SCs for use in future human clinical trials. In the setting of peripheral nerve injury, SCs may be harvested from the injury site itself and expanded in culture while allowing 3–4 weeks for nerve end maturation. This period allows sufficient time for purification and expansion in culture with the added benefit of allowing the surgeon to clearly make out fascicular anatomy at the time of surgery.

Further studies are needed to fully explore whether conduits facilitating oxygen perfusion, magnetic scaffolds using nanoparticles, or scaffolds lined with other cell types such as endothelial cells confer translational advantages in peripheral nerve repair.

Future

Several paradigms remain controversial in peripheral nerve regeneration studies. Though many conduits are currently available and novel conduits continue to emerge, there has not been a definitive consensus established across the literature as to which conduit is superior (Arslantunali et al., 2014; Pabari et al., 2014; Muheremu and Ao, 2015). Contemporary conduits have been engineered to more closely mimic neuronal structure, with longitudinal tracts for cells to orient themselves across. In studies that have successfully loaded SCs into nerve conduits, there are often challenges with maintaining SC viability, especially as conduits become longer to bridge large nerve gaps. Therefore, several studies have been conducted in which nerve conduits are augmented with novel technologies aimed at increasing vascular perfusion, increasing SC stimulation, and facilitating increased SC survival. Studies reviewed herein employed conduits which were augmented via the use of BD™ PuraMatrix™ peptides, crosslinked with genipin, hydrogels made of collagen, fibronectin, or neurotrophic factors, as well as PFTBA to augment oxygen delivery (Chang, 2009; McGrath et al., 2010; Gonzalez-Perez et al., 2018; Ma et al., 2018, 2020). Implementation of magnetic scaffolds and longitudinally oriented magnetic fields has also been utilized to augment nerve regeneration (Gordon, 2016; Liu et al., 2017). Other conduits have been engineered from biomaterials to aid in biocompatibility and biodegradation (Fornasari et al., 2020).

Objective differences in the regeneration of sensory vs. motor nerve fibers is an area of continued investigation. Several studies have demonstrated similar outcomes in sensory and motor nerve regeneration speed and outcomes (Moldovan et al., 2006; Ali et al., 2019). However, other studies suggest the architectural differences between motor and sensory nerves cause different outcomes to be achieved (Moradzadeh et al., 2020).
It has also been suggested that motor or mixed motor-sensory nerve grafts perform superior to sensory nerve grafts in autologous nerve grafting, calling into question whether there exist architectural differences facilitating this superior effect, or differing expression profiles in the SCs corresponding to each of these graft types (Nichols et al., 2004).

On this note, SCs harvested from different nerves may have differing effects on axon regeneration, as their expression profiles may vary. For example, after nerve transection, the proximal stumps of injured peripheral nerves have been shown to down-regulate genes involved in myelination and upregulate genes associated with growth and repair, encouraging the “repair” SC phenotype (Jessen and Mirsky, 2016, 2019). Distal nerve stumps have been noted to upregulate genes associated with clearing cellular debris, making way for the regenerating fibers (Menorca et al., 2013). As each donor site may exhibit a different predominant SC phenotype, the optimal site for SC harvesting, be it the proximal stump of the patient’s injured nerve, the distal stump, or a sensory nerve has yet to be determined. As was investigated by Huang et al. (2019), whether SCs can be harvested and pushed to express genes encouraging neuronal regeneration prior to transplantation remains to be seen. Putting pro-regenerative genes such as c-Jun under transcriptional control of drugs would effectively allow clinicians to manipulate SC phenotypes post-autologous transplantation based on clinical information. As the expression profiles of SCs in the setting of neurotmesis are characterized in increasing detail, studies aiming to transfect and overexpress certain neurotrophic genes within transplanted SCs may provide additional benefits in future studies, allowing clinicians to change expression profiles as appropriate, pushing for regenerative phenotypes in early stages of healing, and for myelination phenotypes after axons have bridged the gap.

One way to achieve the pro-regenerative signal conveyed by SCs and forgo the tedious process of SC harvesting and expansion for transplantation is the use of exosomes. This technology is currently under investigation as a potential alternative or augmentation to autologous SC therapy (Ching and Kingham, 2015; Hessvik and Lorente, 2018; Qing et al., 2018). To collect exosomes, SCs are isolated and observed to express pro-regenerative genes. The ultrafiltrate, containing exosomes, is isolated from the cells and can be loaded into nerve conduits in lieu of SCs or in combination with SCs for use in peripheral nerve repair. Studies are warranted in which conduits loaded with autologous SCs are compared directly to conduits loaded with pro-regenerative exosomes. Having a large supply of exosomes readily available would potentially circumvent the arduous and limiting process of SC harvesting from each patient, overcome the need for immunosuppressive agents, and allow for widespread implementation in the clinic. Therefore, SC exosomes in combination with conduits offer great translational potential and have yet to be fully investigated. We look forward to continued utilization of conduits loaded with autologous SCs for peripheral nerve repair at our institution and others as well as continued studies aimed at optimization of this technology via the use of exosomes in future investigations.

**Limitations**

The 17 studies included in our review investigate varying outcomes relating to SC transplantation, making direct comparisons between studies difficult. Additionally, methodology pertaining to conduits used, number of cells transplanted, and controls implemented varied greatly between studies, which may affect interpretations drawn from pooling the studies together for analysis. All included studies were undertaken using mice or rats as models. These models have been posited to be poor models for human peripheral nerve injury due to their small size, species-specific neurobiological regenerative profile, and unreliable extrapolation to humans (Kaplan et al., 2015). Individual studies were not weighted in any way prior to analysis. One obvious limitation is the paucity of clinical data available regarding autologous SC transplantation in peripheral nerve injury repair. Lastly, further characterization of harvesting, expansion, and transplantation protocol regarding SCs would greatly improve the external validity of the results reviewed.

**Conclusion**

Here, we review 17 in-vivo studies on autologous SC transplantation for use in long-gap, ≥10 mm, peripheral nerve gap repair. This study provides evidence that nerve conduits loaded with autologous SCs are superior to conduits alone. Furthermore, conduits loaded with autologous SCs perform similarly to optimal reversed-autograft controls both by morphometric parameters as well as functional outcomes. Further studies are needed to establish optimal conduit composition, loaded SC cell density, and additional technologies that can be used to augment the regenerative capabilities of SCs in long-gap peripheral nerve injuries.

**Data availability statement**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

**Author contributions**

FV, AD, EE, TS, AK, RS, and AB conducted literature search, drafted, and edited manuscript. Y-SL, SB, and AL directed the project, formulated study idea, and assisted in editing and...
revising manuscript. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Ali, S. A., Rosko, A. J., Hankis, J. E., Stebbins, A. W., Alkhaldi, O., Högikyan, N. D., et al. (2019). Effect of motor versus sensory nerve autografts on regeneration and functional outcomes of rat facial nerve reconstruction. Sci. Rep. 9, 8533. doi: 10.1038/s41598-019-44329-9

Angus, D., Wang, H., Spinner, R. J., Gutierrez-Cotto, Y., Yasemski, M. J., and Windebank, A. J. (2012). A systematic review of animal models used to study nerve regeneration in tissue-engineered scaffolds. Biomaterials 33, 8034–8039. doi: 10.1016/j.biomaterials.2012.07.056

Arlantunali, D., Dursun, T., Yucel, D., Hasirci, N., and Hasirci, V. (2014). Peripheral nerve conduits: technology update. Med. Dev. 7, 405–424. doi: 10.2147/MDER.S55924

Aszmann, O. C., Korak, K. J., Luegmann, M., and Frey, M. (2008). Bridging critical nerve defects through an acellular homograft seeded with autologous schwann cells obtained from a regeneration neuroma of the proximal stump. J. Reconstr. Microsurg. 24, 151–158. doi: 10.1055/s-2008-1076091

Bachelin, C., Lachapelle, F., Girard, C., Moissonnier, P., Serguera-lagache, C., Mallet, J., et al. (2005). Efficient myelin repair in the macaque spinal cord by autologous grafts of Schwann cells. J. Neurosurg. 102, 396–402. doi: 10.1097/01.prs.0000299286.67932.88

Battiston, B., Geuna, S., Ferrero, M., and Tos, P. (2005). Nerve repair by means of tubulization: literature review and personal clinical experience comparing biological and synthetic conduits for sensory nerve repair. Microsurgery 25, 258–267. doi: 10.1002/micr.20127

Belen, D., Aciduman, A., and Er, U. (2009). History of peripheral nerve repair: may the procedure have been practiced in Hippocratic School? Surg. Neurol. 72, 190–3; discussion 193–4. doi: 10.1016/j.surneu.2008.03.030

Bergmeister, K. D., Grosse-hartlage, L., Daeschler, S. C., Rhudius, P., Bocker, A., Beyersdorf, M., et al. (2020). Acute and long-term costs of 268 peripheral nerve injuries in the upper extremity. PLoS ONE 15, e0229530. doi: 10.1371/journal.pone.0229530

Berrocal, Y. A., Almeida, V. W., Gupta, R., and Levi, A. D. (2013). Transplantation of Schwann cells in a collagen tube for the repair of large, peripheral nerve peripheral defects in rats. J. Neurosurg. 119, 720–732. doi: 10.1016/j.tejns.2013.11.001

Burks, S. S., Levi, D. J., Hayes, S., and Levi, A. D. (2014). Challenges in sciatic nerve repair: anatomical considerations. J. Neurosurg. 121, 210–218. doi: 10.3171/2014.2.JNS131667

Burks, S. S., Diaz, A., Haggett, A. E., Oliva, N., Midha, R., and Levi, A. D. (2021). Schwann cell delivery via a novel 3D collagen matrix conduit improves outcomes in critical length nerve gap repairs. J. Neurosurg. 135, 1–11. doi: 10.3171/2020.4.JNS192349

Casella, G. T., Bunge, R. P., and Wood, P. M. (1996). Improved method for harvesting human Schwann cells from mature peripheral nerve and expansion in vitro. Glia 17, 327–338.

Chang, C. J. (2009). The effect of pulse-released nerve growth factor from genipin-crosslinked gelatin in schwann cell-seeded polycaprolactone conduits on large-gap peripheral nerve regeneration. Tissue Eng. Part A 15, 547–557. doi: 10.1089/teng.2007.0342

Ching, R. C., and Kingham, P. J. (2015). The role of exosomes in peripheral nerve regeneration. Neural. Regen. Res. 10, 743–747. doi: 10.4103/1673-5374.156968

Das, S., Sharma, M., Saharia, D., Sarma, K. K., Muit, E. M., and Bora, U. (2017). Electrosprun silk-poly-lactide conduits for functional nerve regeneration in rat sciatic nerve injury model. Biomed. Mater. 12, 045005. doi: 10.1088/1748-605X/aab702

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
nerve repair: conduits and human acellular nerve allograft. J. Physiol. regenerating nerves. Front. Cell. Neurosci.
schwann cell response to nerve injury. functional recovery. doi: 10.3109/10731199.2012.657205
in peripheral nerve. Artif Cells Blood Substit. Immobil. Biotechnol. Different multiple regeneration capacities of moto r and sensory axons and functional recovery after peripheral nerve injury. FASEB J.
J. Mater. Sci. Mater. Med. nerve guidance conduits for humans. of rat models in nerve regeneration research may compromise de signs of doi: 10.1096/fj.201802065RR
World Neurosurg. 223, 496–504. doi: 10.1016/j.expneurol.2010.01.016
Plast Reconstr. Surg. A retrospective case series reporting the outcomes of avance n erve allografts in and wraps for peripheral nerve injury: a review of materials and e fficacy.
J. Neurosci. doi: 10.1097/PRS.0000000000006485
treatment of peripheral nerve injuries. Plast Reconstr. Surg. 114, 1309–1319. doi: 10.1097/PRS.0000000...
Roganovic, Z., Pavlicevic, G., and Petkovic, S. (2005). Missile-induced complete lesions of the tibial nerve and tibial division of the sciatic nerve: results of 119 repairs. *J. Neurosurg.* 103, 622–629. doi: 10.3171/jns.2005.103.4.0622

Safa, B., Jain, S., Desai, M. J., Greenberg, J. A., Niacaris, T. R., Nydick, J. A., et al. (2020). Peripheral nerve repair throughout the body with processed nerve allografts: Results from a large multicenter study. *Microsurgery* 40, 527–537. doi: 10.1002/micr.30574

Stewart, C. E., Kan, C. F. K., Stewart, B. R., Sanicola, H. W., III, Jung, J. P., Sulaiman, O. A. R., et al. (2020). Machine intelligence for nerve conduit design and production. *J. Biol. Eng.* 14, 25. doi: 10.1186/s13036-020-00245-2

Sun, X. H., Che, Y. Q., Tong, X. J., Zhang, L. X., Feng, Y., Xu, A. H., et al. (2009). Improving nerve regeneration of acellular nerve allografts seeded with SCs bridging the sciatic nerve defects of rat. *Cell Mol. Neurosci.* 29, 347–353. doi: 10.1007/s10571-008-9326-6

Taylor, C. A., Braza, D., Rice, J. B., and Dillingham, T. (2008). The incidence of peripheral nerve injury in extremity trauma. *Am. J. Phys. Med. Rehabil.* 87, 381–385. doi: 10.1097/PHM.0b013e31815e6370

Waller, A. (1851). Experiments on the section of the glossopharyngeal and hypoglossal nerves of the frog, and observations of the alterations produced thereby in the structure of their primitive fibres. *Edinb. Med. Surg. J.* 76, 369–376.

Wang, Y., Li, W. Y., Jia, H., Zhai, F. G., Qu, W. R., Cheng, Y. X., et al. (2017). KLF7-transfected Schwann cell graft transplantation promotes sciatic nerve regeneration. *Neuroscience* 340, 319–332. doi: 10.1016/j.neuroscience.2016.10.069

Yao, C., Wang, Q., Wang, Y., Wu, J., Cao, X., Lu, Y., et al. (2021). Loc688254 regulates Schwann cell proliferation through Psc1 and Skat as a microRNA sponge following sciatic nerve injury. *Glia* 69, 2391–2403. doi: 10.1002/glia.24045